Takeda has sued Mylan for patent infringement and breach of a licencing agreement over Takeda’s Colcrys drug.
New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
US presidential candidates Bernie Sanders and Cory Booker have tabled a bill that would force drug companies to adhere to government-set prices-or risk losing patent exclusivity.
The Russian government has endorsed legislation that would allow it to employ compulsory drug licensing in emergencies.
A Chinese state-owned chemical firm is suing US crop protection products company Atticus for patent infringement.
Novartis has agreed to buy the Japanese business of South African generics manufacturer Aspen Pharmacare for a potential €400 million.
Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
German pharmaceutical company Stada Arzneimittel has acquired a portfolio of products from Takeda for $660 million.